Oxford Malaria vaccine has been approved by the World Health Organisation (WHO), for global use especially in Africa where clinical trials were conducted in Ghana and Malawi.
Results from clinical trials according to the India production company and Oxford showed 75% efficacy prompting some medical personnel in the continent to continue with the traditional western treatment.
According to the India manufacturers, a dose of the vaccine would cost a little less than $4 and 20,000 vaccines were produced at risk for the clinical trials to earn WHO approval. With the nod from WHO the company would be able to produce 100million vaccines a year.
Despite earning 75% clinical efficacy the producing company said the final phase of trials surpassed expectations.